AstraZeneca, Samsung Biologics Settle Soliris Biosimilar Lawsuit

An AstraZeneca Plc unit settled a federal patent-infringement lawsuit with a Samsung Biologics Co. subsidiary after failing to block its biosimilar version of the $500,000-per-patient drug Soliris.

Judge Gregory B. Williams on Tuesday approved the stipulation of dismissal without prejudice in the US District Court for the District of Delaware, leaving open the option for Alexion Pharmaceuticals Inc. and Samsung Bioepis Co. to renew their allegations. No further details were provided in the filing. The settlement comes after Alexion was rejected in multiple requests to block the biosimilar while it appeals Williams’ May denial of its motion for an order ...